Environmental factors and autoimmune thyroiditis
Nature Clinical Practice Endocrinology & Metabolism 4, 454 (2008). Author: Leonidas H Duntas Ver artigo completo
CE aprova dosagem semanal de Enbrel para psoríase moderada a grave
A Comissão Europeia (CE) aprovou a comercialização da versão de 50 miligramas de administração semanal do fármaco Enbrel (etanercept), da Wyeth, como alternativa à actual versão de 25 miligramas, administrada duas vezes por semana, para pacientes com psoríase em placas moderada a grave. Ver artigo completo
Advances in the use of biologic agents for the treatment of systemic vasculitis
[Vasculitis syndromes: Edited by Phil Seo] Chung, Sharon A; Seo, Philip. Purpose of review: Due to the well known toxicities of cyclophosphamide, substantial interest exists in finding other therapies to treat primary systemic vasculitis. Biologic agents have been proposed as an alternative to cyclophosphamide for these disorders because of their recent success in treating other rheumatic [...]
Molecular effects of exercise in patients with inflammatory rheumatic disease
Nature Clinical Practice Rheumatology 4, 597 (2008). Authors: Ingrid E Lundberg & Gustavo A Nader Ver artigo completo
Enbrel aprovado na Europa para a psoríase infantil
A Comissão Europeia (CE) aprovou a comercialização do fármaco biológico Enbrel (etanercept), da Wyeth, para o tratamento da psoríase em placas grave em crianças. Este é o primeiro medicamento aprovado para esta indicação. A aprovação desta nova indicação já era esperada, visto vir no seguimento da recomendação positiva da Agência Europeia do Medicamento (EMEA), em Novembro [...]
Certolizumab pegol
Nature Reviews Drug Discovery 7, 641 (2008). Authors: Gil Y. Melmed, Stephan R. Targan, Uma Yasothan, Delphine Hanicq & Peter Kirkpatrick In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies. Ver [...]
Algorithm that predicts progression of undifferentiated arthritis has been validated
Nature Clinical Practice Rheumatology 4, 565 (2008). Ver artigo completo
Transcription profiling of rheumatic diseases
Lisa GM van Baarsen, Carina L Bos, Tineke CTM van der Pouw Kraan and Cornelis L Verweij Arthritis Research & Therapy - Latest articles Rheumatic diseases represent a diverse group of disorders. Most of these diseases are heterogeneous in nature, and show varying responsiveness to treatment. Since our understanding of the molecular complexity is incomplete and [...]
Stanford Develops Imaging Technique To Catch Arthritis Early In Onset
Arthritis / Rheumatology News From Medical News Today You come into a doctor's office with severe knee pain. The physician orders an MRI, which reveals substantial loss of cartilage-osteoarthritis, that is-in your knee joint. At this point, not much can be done beyond gulping down palliatives and trying to keep your weight off the joint. But [...]
Potential New Antibody Treatment For Autoimmune Diseases Discovered By Scientists At UCSF
Arthritis / Rheumatology News From Medical News Today Scientists at UCSF have discovered an abnormality in a patient's immune system that may lead to safer therapies for autoimmune diseases such as rheumatoid arthritis and colitis, as well as potential new ways to treat transplant rejection. The research identified antibodies from a woman's immune system that prevent [...]